Delaware | 1-815 | 51-0014090 | ||
(State or Other Jurisdiction | (Commission | (I.R.S. Employer | ||
Of Incorporation) | File Number) | Identification No.) |
E. I. DU PONT DE NEMOURS AND COMPANY | |
(Registrant) | |
/s/ Jeanmarie F. Desmond | |
Jeanmarie F. Desmond | |
Vice President and Controller |
Exhibit 99.1 | |||||
April 25, 2017 | Media Contact: | Dan Turner | |||
WILMINGTON, Del. | 302-996-8372 | ||||
daniel.a.turner@dupont.com | |||||
Investor Contact: | 302-774-4994 |
• | GAAP1 earnings per share increased 9 percent to $1.52 from $1.39 in prior year. Operating earnings2 per share increased 30 percent to $1.64 from $1.26 in prior year. |
• | Sales of $7.7 billion increased 5 percent on a 4-percent benefit from volume and a 1-percent benefit from local price. Sales grew in most segments, led by Agriculture, Performance Materials, and Electronics & Communications. |
• | Agriculture sales increased 4 percent reflecting benefits from local price and volume. Pricing growth was driven by double-digit gains in Latin America, the launch of new soybean varieties in North America and increased sunflower seed sales in Europe. Volume growth was driven by the change in timing of seed deliveries and increased insecticide and sunflower seed volumes, partially offset by lower expected corn acreage in North America. |
• | Total company gross margin expanded by more than 80 basis points. Segment operating margins expanded by about 250 basis points, led by improvements in Electronics & Communications, Performance Materials and Agriculture. |
• | Free cash flow3 improved over $200 million. |
• | DuPont expects first-half 2017 GAAP1 earnings per share of about $2.42, a decrease of about 5 percent versus prior year. First-half 2017 operating earnings2 per share are expected to be about $2.90, an increase of about 16 percent versus prior year. |
Three Months Ended | |||||||||||||||||||
March 31, 2017 | Percentage Change Due to: | ||||||||||||||||||
(Dollars in millions) | $ | % Change | Local Price and Product Mix | Currency | Volume | Portfolio/Other | |||||||||||||
U.S. & Canada | $ | 3,576 | — | 1 | — | (1 | ) | — | |||||||||||
EMEA* | 2,110 | 5 | 1 | (3 | ) | 8 | (1 | ) | |||||||||||
Asia Pacific | 1,451 | 13 | (1 | ) | (1 | ) | 16 | (1 | ) | ||||||||||
Latin America | 606 | 14 | 7 | 11 | (3 | ) | (1 | ) | |||||||||||
Total Consolidated Net Sales | $ | 7,743 | 5 | 1 | — | 4 | — | ||||||||||||
* Europe, Middle East & Africa |
Three Months Ended | |||||||||||||||||||
March 31, 2017 | Percentage Change Due to: | ||||||||||||||||||
(Dollars in millions) | $ | % Change | Local Price and Product Mix | Currency | Volume | Portfolio/Other | |||||||||||||
Agriculture | $ | 3,928 | 4 | 2 | 1 | 2 | (1 | ) | |||||||||||
Electronics & Communications | 510 | 13 | — | (1 | ) | 15 | (1 | ) | |||||||||||
Industrial Biosciences | 368 | 5 | 2 | (1 | ) | 4 | — | ||||||||||||
Nutrition & Health | 789 | (1 | ) | — | (1 | ) | — | — | |||||||||||
Performance Materials | 1,368 | 10 | — | (1 | ) | 11 | — | ||||||||||||
Protection Solutions | 747 | 2 | (2 | ) | (1 | ) | 5 | — | |||||||||||
Other | 33 | ||||||||||||||||||
Consolidated Net Sales | $ | 7,743 | 5 | 1 | — | 4 | — |
Operating Earnings - 1st Quarter | ||||||||||||||||
Change vs. 2016 | ||||||||||||||||
(Dollars in millions) | 1Q17 | 1Q16 | $ | % | ||||||||||||
Agriculture | $ | 1,236 | $ | 1,101 | $ | 135 | 12 | % | ||||||||
Electronics & Communications | 89 | 59 | 30 | 51 | % | |||||||||||
Industrial Biosciences | 75 | 63 | 12 | 19 | % | |||||||||||
Nutrition & Health | 121 | 104 | 17 | 16 | % | |||||||||||
Performance Materials | 355 | 273 | 82 | 30 | % | |||||||||||
Protection Solutions | 177 | 176 | 1 | 1 | % | |||||||||||
Other | (62 | ) | (59 | ) | (3 | ) | -5 | % | ||||||||
Total segment operating earnings (4) | 1,991 | 1,717 | 274 | 16 | % | |||||||||||
Exchange gains (losses) (5) | (59 | ) | (121 | ) | 62 | nm | ||||||||||
Corporate expenses (4) | (69 | ) | (86 | ) | 17 | -20 | % | |||||||||
Interest expense | (84 | ) | (92 | ) | 8 | -9 | % | |||||||||
Operating earnings before income taxes (2) | 1,779 | 1,418 | 361 | 25 | % | |||||||||||
Provision for income taxes on operating earnings (2) (4) | (338 | ) | (303 | ) | (35 | ) | ||||||||||
Less: Net loss attributable to noncontrolling interests | 8 | 6 | 2 | |||||||||||||
Operating earnings (2) | $ | 1,433 | $ | 1,109 | $ | 324 | 29 | % | ||||||||
Operating earnings per share (2) | $ | 1.64 | $ | 1.26 | $ | 0.38 | 30 | % | ||||||||
GAAP (1) earnings per share | $ | 1.52 | $ | 1.39 | $ | 0.13 | 9 | % | ||||||||
(4) See Schedules B and C for listing of significant items and their impact by segment. | ||||||||||||||||
(5) See Schedule D for additional information on exchange gains and losses. |
SCHEDULE A | |||||||
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Net sales | $ | 7,743 | $ | 7,405 | |||
Cost of goods sold | 4,371 | 4,242 | |||||
Other operating charges (1) | 204 | 185 | |||||
Selling, general and administrative expenses (1) | 1,260 | 1,128 | |||||
Research and development expense | 416 | 418 | |||||
Other income, net (1) | (306 | ) | (372 | ) | |||
Interest expense | 84 | 92 | |||||
Employee separation / asset related charges, net (1) | 152 | 77 | |||||
Income from continuing operations before income taxes | 1,562 | 1,635 | |||||
Provision for income taxes on continuing operations (1) | 224 | 406 | |||||
Income from continuing operations after income taxes | 1,338 | 1,229 | |||||
(Loss) income from discontinued operations after income taxes | (217 | ) | 3 | ||||
Net income | 1,121 | 1,232 | |||||
Less: Net income attributable to noncontrolling interests | 8 | 6 | |||||
Net income attributable to DuPont | $ | 1,113 | $ | 1,226 | |||
Basic earnings per share of common stock: | |||||||
Basic earnings per share of common stock from continuing operations | $ | 1.53 | $ | 1.40 | |||
Basic loss per share of common stock from discontinued operations | (0.25 | ) | — | ||||
Basic earnings per share of common stock (2) | $ | 1.28 | $ | 1.40 | |||
Diluted earnings per share of common stock: | |||||||
Diluted earnings per share of common stock from continuing operations | $ | 1.52 | $ | 1.39 | |||
Diluted loss per share of common stock from discontinued operations | (0.25 | ) | — | ||||
Diluted earnings per share of common stock (2) | $ | 1.27 | $ | 1.39 | |||
Dividends per share of common stock | $ | 0.38 | $ | 0.38 | |||
Average number of shares outstanding used in earnings per share (EPS) calculation: | |||||||
Basic | 866,516,000 | 873,546,000 | |||||
Diluted | 871,083,000 | 877,251,000 | |||||
Reconciliation of Non-GAAP Measures | ||||||||||
Summary of Earnings Comparison | ||||||||||
Three Months Ended March 31, | ||||||||||
2017 | 2016 | % Change | ||||||||
Income from continuing operations after income taxes (GAAP) | $ | 1,338 | $ | 1,229 | 9 | % | ||||
Less: Significant items (charge) benefit included in income from continuing operations after income taxes (per Schedule B) | (36 | ) | 160 | |||||||
Non-operating pension/OPEB costs included in income from continuing operations after income taxes | (67 | ) | (46 | ) | ||||||
Net income attributable to noncontrolling interest from continuing operations | 8 | 6 | ||||||||
Operating earnings (Non-GAAP) (3) | $ | 1,433 | $ | 1,109 | 29 | % | ||||
Earnings per share from continuing operations (GAAP) | $ | 1.52 | $ | 1.39 | 9 | % | ||||
Less: Significant items (charge) benefit included in EPS (per Schedule B) | (0.04 | ) | 0.18 | |||||||
Non-operating pension/OPEB costs included in EPS | (0.08 | ) | (0.05 | ) | ||||||
Operating earnings per share (Non-GAAP) (3) | $ | 1.64 | $ | 1.26 | 30 | % | ||||
SCHEDULE A (continued) | ||||||||
March 31, 2017 | December 31, 2016 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 3,347 | $ | 4,605 | ||||
Marketable securities | 2,570 | 1,362 | ||||||
Accounts and notes receivable, net | 7,272 | 4,971 | ||||||
Inventories | 5,287 | 5,673 | ||||||
Prepaid expenses | 574 | 506 | ||||||
Total current assets | 19,050 | 17,117 | ||||||
Property, plant and equipment, net of accumulated depreciation (March 31, 2017 - $14,994; December 31, 2016 - $14,736) | 9,084 | 9,231 | ||||||
Goodwill | 4,172 | 4,180 | ||||||
Other intangible assets | 3,624 | 3,664 | ||||||
Investment in affiliates | 687 | 649 | ||||||
Deferred income taxes | 3,382 | 3,308 | ||||||
Other assets | 1,851 | 1,815 | ||||||
Total | $ | 41,850 | $ | 39,964 | ||||
Liabilities and Equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 3,038 | $ | 3,705 | ||||
Short-term borrowings and capital lease obligations | 2,279 | 429 | ||||||
Income taxes | 185 | 101 | ||||||
Other accrued liabilities | 4,308 | 4,662 | ||||||
Total current liabilities | 9,810 | 8,897 | ||||||
Long-term borrowings and capital lease obligations | 8,099 | 8,107 | ||||||
Other liabilities | 11,911 | 12,333 | ||||||
Deferred income taxes | 395 | 431 | ||||||
Total liabilities | 30,215 | 29,768 | ||||||
Commitments and contingent liabilities | ||||||||
Stockholders' equity | ||||||||
Preferred stock | 237 | 237 | ||||||
Common stock, $0.30 par value; 1,800,000,000 shares authorized; Issued at March 31, 2017 - 953,937,000; December 31, 2016 - 950,044,000 | 286 | 285 | ||||||
Additional paid-in capital | 11,354 | 11,190 | ||||||
Reinvested earnings | 15,704 | 14,924 | ||||||
Accumulated other comprehensive loss | (9,423 | ) | (9,911 | ) | ||||
Common stock held in treasury, at cost (87,041,000 shares at March 31, 2017 and December 31, 2016) | (6,727 | ) | (6,727 | ) | ||||
Total DuPont stockholders' equity | 11,431 | 9,998 | ||||||
Noncontrolling interests | 204 | 198 | ||||||
Total equity | 11,635 | 10,196 | ||||||
Total | $ | 41,850 | $ | 39,964 |
SCHEDULE A (continued) | |||||||
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Total Company | |||||||
Net income | $ | 1,121 | $ | 1,232 | |||
Adjustments to reconcile net income to cash used for operating activities: | |||||||
Depreciation | 230 | 238 | |||||
Amortization of intangible assets | 51 | 122 | |||||
Net periodic pension benefit cost | 109 | 146 | |||||
Contributions to pension plans | (82 | ) | (88 | ) | |||
Gain on sale of businesses and other assets | (192 | ) | (374 | ) | |||
Asset-related charges | 119 | 78 | |||||
Other operating activities - net | 78 | 180 | |||||
Change in operating assets and liabilities - net | (3,058 | ) | (3,340 | ) | |||
Cash used for operating activities | (1,624 | ) | (1,806 | ) | |||
Investing activities | |||||||
Purchases of property, plant and equipment | (330 | ) | (357 | ) | |||
Investments in affiliates | (22 | ) | (1 | ) | |||
Proceeds from sale of businesses and other assets - net | 283 | 193 | |||||
Net (increase) decrease in short-term financial instruments | (1,205 | ) | 282 | ||||
Foreign currency exchange contract settlements | (15 | ) | (78 | ) | |||
Other investing activities - net | (46 | ) | (12 | ) | |||
Cash (used for) provided by investing activities | (1,335 | ) | 27 | ||||
Financing activities | |||||||
Dividends paid to stockholders | (331 | ) | (334 | ) | |||
Net increase in borrowings | 1,844 | 958 | |||||
Proceeds from exercise of stock options | 160 | 36 | |||||
Other financing activities - net | (32 | ) | (35 | ) | |||
Cash provided by financing activities | 1,641 | 625 | |||||
Effect of exchange rate changes on cash | 60 | 20 | |||||
Decrease in cash and cash equivalents | (1,258 | ) | (1,134 | ) | |||
Cash and cash equivalents at beginning of period | 4,605 | 5,300 | |||||
Cash and cash equivalents at end of period | $ | 3,347 | $ | 4,166 | |||
Reconciliation of Non-GAAP Measure | |||||||
Calculation of Free Cash Flow - Total Company | |||||||
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Cash used for operating activities (GAAP) | $ | (1,624 | ) | $ | (1,806 | ) | |
Purchases of property, plant and equipment | (330 | ) | (357 | ) | |||
Free cash flow (Non-GAAP) | $ | (1,954 | ) | $ | (2,163 | ) | |
(1) See Schedule B for detail of significant items. | |||||||
(2) The sum of the individual earnings per share amounts from continuing operations and discontinued operations may not equal the total company earnings per share amounts due to rounding. | |||||||
(3) Operating earnings and operating earnings per share are defined as earnings from continuing operations excluding significant items and non-operating pension/OPEB costs. Non-operating pension/OPEB costs includes all of the components of net periodic benefit cost from continuing operations with the exception of the service cost component. |
SCHEDULE B | ||||||||||||||||||||||||
SIGNIFICANT ITEMS | ||||||||||||||||||||||||
Pre-tax | After-tax (6) | ($ Per Share) | ||||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | 2017 | 2016 | |||||||||||||||||||
1st Quarter | ||||||||||||||||||||||||
Transaction costs (1) | $ | (170 | ) | $ | (24 | ) | $ | (122 | ) | $ | (21 | ) | $ | (0.14 | ) | $ | (0.02 | ) | ||||||
Restructuring charges, net (2) | (152 | ) | (77 | ) | (100 | ) | (48 | ) | (0.11 | ) | (0.06 | ) | ||||||||||||
Gain on sale of business / entity (3) | 162 | 369 | 86 | 214 | 0.10 | 0.24 | ||||||||||||||||||
Income tax items (4) | 47 | — | 100 | — | 0.11 | — | ||||||||||||||||||
Customer claims adjustment/recovery (5) | — | 23 | — | 15 | — | 0.02 | ||||||||||||||||||
1st Quarter - Total | $ | (113 | ) | $ | 291 | $ | (36 | ) | $ | 160 | $ | (0.04 | ) | $ | 0.18 | |||||||||
(1) | First quarter 2017 and 2016 included charges of $(170) and $(24), respectively, recorded in selling, general and administrative expenses related to costs associated with the planned merger with The Dow Chemical Company and related activities. For first quarter 2017 and 2016, the effective tax rate for the total of pre-tax charges was 28.2% and 12.5%, respectively. A significant portion of the transaction costs are in the US; however, those costs are not always tax-deductible. | |||||||||||
(2) | First quarter 2017 included a $(152) restructuring charge recorded in employee separation/asset related charges, net, primarily associated with actions to improve plant productivity. The charge included $(33) of severance and related benefit costs and $(119) of asset-related charges. The asset-related charges mainly consists of accelerated depreciation associated with decision to close the Company’s Protection Solutions Cooper River manufacturing site located near Charleston, South Carolina. Additional charges for accelerated depreciation are expected in 2017, the majority of which will be recognized in the second quarter. | |||||||||||
First quarter 2016 included a $(75) restructuring charge recorded in employee separation / asset related charges, net related to the decision not to re-start the Agriculture segment's insecticide manufacturing facility at the La Porte site located in La Porte, Texas. The charge included $(41) of asset-related charges, $(18) of contract termination costs, and $(16) of employee severance and related benefit costs. | ||||||||||||
First quarter 2016 included a $(2) charge in employee separation/asset related charges, net associated with the 2016 Global Cost Savings and Restructuring Program. This charge was primarily due to the identification of additional projects in certain segments, offset by reduction in severance and related benefit costs due to workforce reductions achieved through non-severance programs. | ||||||||||||
(3) | First quarter 2017 included a gain of $162 recorded in other income, net associated with the sale of the company's global food safety diagnostic business, a part of the Nutrition & Health segment. The effective tax rate for the gain on sale was 46.9% due to unfavorable tax consequences of non-deductible goodwill. | |||||||||||
First quarter 2016 included a gain of $369 recorded in other income, net associated with the sale of the DuPont (Shenzhen) Manufacturing Limited entity, which held certain buildings and other assets. The gain is reflected as a Corporate item. | ||||||||||||
(4) | First quarter 2017 included a tax benefit of $53, as well as a $47 benefit on associated accrued interest reversals (recorded in other income, net), related to a reduction in the company’s unrecognized tax benefits due to the closure of various tax statutes of limitations. | |||||||||||
(5) | First quarter 2016 included a benefit of $23, in other operating charges for reductions in the accrual for customer claims related to the use of the Imprelis® herbicide. | |||||||||||
(6) | Unless specifically addressed in notes above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. | |||||||||||
SCHEDULE C | ||||||||
Three Months Ended March 31, | ||||||||
SEGMENT NET SALES | 2017 | 2016 | ||||||
Agriculture | $ | 3,928 | $ | 3,786 | ||||
Electronics & Communications | 510 | 452 | ||||||
Industrial Biosciences | 368 | 352 | ||||||
Nutrition & Health | 789 | 801 | ||||||
Performance Materials | 1,368 | 1,249 | ||||||
Protection Solutions | 747 | 729 | ||||||
Other | 33 | 36 | ||||||
Consolidated net sales | $ | 7,743 | $ | 7,405 | ||||
Three Months Ended March 31, | ||||||||
SEGMENT OPERATING EARNINGS (1) | 2017 | 2016 | ||||||
Agriculture | $ | 1,236 | $ | 1,101 | ||||
Electronics & Communications | 89 | 59 | ||||||
Industrial Biosciences | 75 | 63 | ||||||
Nutrition & Health | 121 | 104 | ||||||
Performance Materials | 355 | 273 | ||||||
Protection Solutions | 177 | 176 | ||||||
Other | (62 | ) | (59 | ) | ||||
Total segment operating earnings | 1,991 | 1,717 | ||||||
Corporate expenses | (69 | ) | (86 | ) | ||||
Interest expense | (84 | ) | (92 | ) | ||||
Operating earnings before income taxes and exchange losses | 1,838 | 1,539 | ||||||
Exchange losses(2) | (59 | ) | (121 | ) | ||||
Operating earnings before income taxes (Non-GAAP) | $ | 1,779 | $ | 1,418 | ||||
Non-operating pension/OPEB costs | (104 | ) | (74 | ) | ||||
Total significant items before income taxes | (113 | ) | 291 | |||||
Income from continuing operations before income taxes (GAAP) | $ | 1,562 | $ | 1,635 | ||||
Three Months Ended March 31, | ||||||||
SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX) (3) | 2017 | 2016 | ||||||
Agriculture | $ | — | $ | (73 | ) | |||
Electronics & Communications | (5 | ) | 7 | |||||
Industrial Biosciences | (6 | ) | 1 | |||||
Nutrition & Health | 160 | 1 | ||||||
Performance Materials | (11 | ) | (4 | ) | ||||
Protection Solutions | (124 | ) | 3 | |||||
Other | — | (3 | ) | |||||
Total significant items by segment | 14 | (68 | ) | |||||
Corporate expenses | (127 | ) | 359 | |||||
Total significant items before income taxes | $ | (113 | ) | $ | 291 |
SCHEDULE C (continued) |
Corporate Expenses | ||||||||||
The reconciliation below reflects GAAP corporate expenses (income) excluding significant items. | ||||||||||
Three Months Ended March 31, | ||||||||||
2017 | 2016 | |||||||||
Corporate expenses (income) (GAAP) | $ | 196 | $ | (273 | ) | |||||
Less: Significant items charge (benefit) (3) | 127 | (359 | ) | |||||||
Corporate expenses (Non-GAAP) | $ | 69 | $ | 86 | ||||||
(1) Segment operating earnings is defined as income (loss) from continuing operations before income taxes excluding significant pre-tax benefits (charges), non-operating pension/OPEB costs, exchange gains (losses), corporate expenses and interest. | ||||||||||
(2) See Schedule D for additional information on exchange gains and losses. | ||||||||||
(3) See Schedule B for detail of significant items. |
SCHEDULE D | |||||||||
Reconciliations of Adjusted EBIT / EBITDA to Consolidated Income Statements | |||||||||
Three Months Ended March 31, | |||||||||
2017 | 2016 | ||||||||
Income from continuing operations after income taxes (GAAP) | $ | 1,338 | $ | 1,229 | |||||
Add: Provision for income taxes on continuing operations | 224 | 406 | |||||||
Income from continuing operations before income taxes | $ | 1,562 | $ | 1,635 | |||||
Add: Significant items charge (benefit) before income taxes(1) | 113 | (291 | ) | ||||||
Add: Non-operating pension/OPEB costs | 104 | 74 | |||||||
Operating earnings before income taxes (Non-GAAP) | $ | 1,779 | $ | 1,418 | |||||
Less: Net income attributable to noncontrolling interests from continuing operations | 8 | 6 | |||||||
Add: Interest expense | 84 | 92 | |||||||
Adjusted EBIT from operating earnings (Non-GAAP) | $ | 1,855 | $ | 1,504 | |||||
Add: Depreciation and amortization | 281 | 360 | |||||||
Adjusted EBITDA from operating earnings (Non-GAAP) | $ | 2,136 | $ | 1,864 |
Reconciliation of Operating Costs to Consolidated Income Statement Line Items | |||||||||||||||||||||||||
GAAP operating costs is defined as other operating charges, selling, general and administrative expenses, and research and development expense. The reconciliation below reflects operating costs excluding significant items and non-operating pension/OPEB costs. | |||||||||||||||||||||||||
Three Months Ended March 31, 2017 | Three Months Ended March 31, 2016 | ||||||||||||||||||||||||
As Reported (GAAP) | Less: Significant Items (1) | Less: Non-Operating Pension/OPEB Costs | (Non-GAAP) | As Reported (GAAP) | Less: Significant Items (1) | Less: Non-Operating Pension/OPEB Costs | (Non-GAAP) | ||||||||||||||||||
Other operating charges | $ | 204 | $ | — | $ | — | $ | 204 | $ | 185 | $ | (23 | ) | $ | — | $ | 208 | ||||||||
Selling, general and administrative expenses | 1,260 | 170 | 31 | 1,059 | 1,128 | 24 | 30 | 1,074 | |||||||||||||||||
Research and development expense | 416 | — | 16 | 400 | 418 | — | 11 | 407 | |||||||||||||||||
Total | $ | 1,880 | $ | 170 | $ | 47 | $ | 1,663 | $ | 1,731 | $ | 1 | $ | 41 | $ | 1,689 |
Reconciliation of Operating Earnings Per Share (EPS) Outlook | |||||||||
The reconciliation below represents the company's outlook on an operating earnings basis, defined as earnings excluding significant items and non-operating pension/OPEB costs. | |||||||||
Six Months Ended June 30, | |||||||||
2017 Outlook | 2016 Actual | ||||||||
EPS from continuing operations (GAAP) | $ | 2.42 | $ | 2.55 | |||||
Significant items (1) | |||||||||
Transaction costs | (0.30 | ) | (0.09 | ) | |||||
Gain on sale of business / entity | 0.10 | 0.24 | |||||||
Restructuring charges / adjustments | (0.23 | ) | 0.01 | ||||||
Income tax items | 0.11 | — | |||||||
Customer claims adjustment/recovery | — | 0.04 | |||||||
Non-operating pension/OPEB costs - estimate | (0.16 | ) | (0.15 | ) | |||||
Operating EPS (Non-GAAP) | $ | 2.90 | $ | 2.50 |
SCHEDULE D (continued) | ||||||||
Exchange Gains/Losses on Operating Earnings | ||||||||
The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes. The net pre-tax exchange gains and losses are recorded in other loss, net and the related tax impact is recorded in provision for (benefit from) income taxes on the Consolidated Income Statements. | ||||||||
Three Months Ended March 31, | ||||||||
2017 | 2016 | |||||||
Subsidiary Monetary Position Gain (Loss) | ||||||||
Pre-tax exchange gains | $ | 26 | $ | 33 | ||||
Local tax benefits | 36 | 13 | ||||||
Net after-tax impact from subsidiary exchange gains | $ | 62 | $ | 46 | ||||
Hedging Program Gain (Loss) | ||||||||
Pre-tax exchange losses | $ | (85 | ) | $ | (154 | ) | ||
Tax benefits | 30 | 55 | ||||||
Net after-tax impact from hedging program exchange losses | $ | (55 | ) | $ | (99 | ) | ||
Total Exchange Gain (Loss) | ||||||||
Pre-tax exchange losses | $ | (59 | ) | $ | (121 | ) | ||
Tax benefits | 66 | 68 | ||||||
Net after-tax exchange gains (losses) | $ | 7 | $ | (53 | ) | |||
As shown above, the "Total Exchange Gain (Loss)" is the sum of the "Subsidiary Monetary Position Gain (Loss)" and the "Hedging Program Gain (Loss)." | ||||||||
SCHEDULE D (continued) | |||||||
Reconciliation of Base Income Tax Rate to Effective Income Tax Rate | |||||||
Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), as defined above, significant items and non-operating pension/OPEB costs. | |||||||
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Income from continuing operations before income taxes (GAAP) | $ | 1,562 | $ | 1,635 | |||
Add: Significant items - charge (benefit) (1) | 113 | (291 | ) | ||||
Non-operating pension/OPEB costs | 104 | 74 | |||||
Less: Exchange losses | (59 | ) | (121 | ) | |||
Income from continuing operations before income taxes, significant items, exchange losses, and non-operating pension/OPEB costs (Non-GAAP) | $ | 1,838 | $ | 1,539 | |||
Provision for income taxes on continuing operations (GAAP) | $ | 224 | $ | 406 | |||
Add: Tax benefits (expenses) on significant items | 77 | (131 | ) | ||||
Tax benefits on non-operating pension/OPEB benefits/costs | 37 | 28 | |||||
Tax benefits on exchange losses | 66 | 68 | |||||
Provision for income taxes on continuing earnings, excluding exchange losses (Non-GAAP) | $ | 404 | $ | 371 | |||
Effective income tax rate (GAAP) | 14.3 | % | 24.8 | % | |||
Significant items and non-operating pension/OPEB costs effect | 4.7 | % | (3.4 | )% | |||
Tax rate, from continuing operations before significant items and non-operating pension/OPEB costs | 19.0 | % | 21.4 | % | |||
Exchange gains (losses) effect | 3.0 | % | 2.7 | % | |||
Base income tax rate from continuing operations (Non-GAAP) | 22.0 | % | 24.1 | % | |||
(1) See Schedule B for detail of significant items. | |||||||
*!;F/2 @+8PR^>R!J0]""7+D.[)0+
\=ITO<"6!NEM::JKYE>ET?28(Z6&38G)\W7)\A[<==ZEFZWJ=-
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M/:'_ /4#2?7B_P R_P# 2WP]/U.+)
M& \_P XP.$Q<4\^7S8>0,Q4;7 NB<3.=G $'8\^
M26+IVJA.,I:EM)]J[_>7K/:GHNHT^3#BZ1"$I)I235Q;7#7N+MW[G-XZ]#O/
M^(>V7B'M#X<[3\9P?F&;.HLP.!=WD;-#&EG>"9M@F,'D.G@L\W2,D]1+48\V
MUOT7_F=/3_;?2Z;I&'I.LT"S1Q_K25-VW=.+KOZGM>R#L2XZ[/>+7YKQ'VN9
MOQQEQPLD RS'0O;&'N+2V2S*X6VCT_*YKLTFBSX,F_)G$P7#?$& A8
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MN*ECE4U^=>-S*EV[4=VBG@D^B/0)QP/)DXD[EN5I\KBO1)(^@<)\:\/<$>
MDO'BN(\^RW(<+-V;Y7%'-F>+9AV/?WK3I!>0":!->2[<.;'AUEY))+8N[KS/
MGM;H=7K_ &?<-)BED:U61M13;2I\\'Z/FS3A[BW@O%XYN983,>&<9@YA+CL+
MB0Z!^'TN;*X2,/( /!+38H]0OH)3Q9<3E=Q:/YC'#J]'JXX]CCFC)4FN5*TU
MP_V<,_)_ /%? O:1Q;PIFG#N9Y)P;PIP%@LQAX
TN$/DHLO:7-@\E
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M
&3$'/;DCQP\,J?%OR6BS#\,S2L ^"T\8G89I!]2T\;XD^&9W]0M5F,]AG<
MM5E0.#*7J_&,W!E+^JT686PJ>M8Y+!XRLA:+)\2' K<+*M9"' K1R<5QT9'67EQ]ZZ8].D8O48
M8^9S9^-GV:N^"VCH()]CGEU2;X1DDXCF==N?7FY;K1Q7D8OJ&2NYF?GQ/.5H]Y6JTT?0Q
M>MG+S*'9_P!!*7?Y+5K' O0AZJ;[LJ=G3C="0CY!7X/P,Y9WZE+\WD%#U&C^
MD;3\(CQ6RIV=Z/:Q,8)_- W2\)>8_$?J5NS^,7JG(.^Y"QI!XC]2N7/\.!
MN\R'WGY)[ \1^I6WB:$470[>14O$A^*#>)VAKOQ+:/(^"CPD5XC]0=Q-(2-
M:S>_5W%(V#\1^I6[B2<"N\ OD?%1L-/%EZE1SZ;5J$QL;W:S\-&\N%4\U7BN&>(ZXY*.GA^(* !>X_%<4\)UQS'0P_$+VG:1P]RX
M9X5Z'3'+9Z#*N)2"-4A '4BUY>3"=<,C/88#B^#NV@ M#=W2/.Y]PZ+S
8S/BX2.MDFYZVO1Q:
M9!^%*A.98W. #1OX% E
M,U19H0P.#I-//=IKYI58WDHOBSP7[7R*6P%E-$6>.;R?5>"'CL?BG2PW%.(A
M/\*X"QL3:P\&RXY3J8;C&<#=S3]2SEIS593I8?C4M(L$>;7+-Z:T5XU'7PG'
M(._>N://DN:6E-(YWZG8PO&K7:3WC3X&Z*YI:.+[G2M5).CLX7C